New machine learning models and novel analysis methods address
customer requests
LANCASTER, Calif.–(BUSINESS WIRE)–Simulations Plus, Inc. (Nasdaq:SLP), the leading provider of modeling
and simulation solutions for the pharmaceutical, biotechnology,
chemicals, and consumer goods industries, today announced that it has
released version 9.5 of its flagship machine learning modeling platform, ADMET
Predictor®.
Key improvements include:
-
Novel approaches to calculate uncertainty estimates on all regression
models -
New machine learning models for important metabolism and transporter
endpoints -
New machine learning models for AMES mutagenicity, a primary toxicity
endpoint required during risk assessment -
New Structure Sensitivity Analysis visualization tool to easily map
atom-level contributions to model predictions -
Improved rat-specific models to more accurately inform HTPK Simulation
predictions -
Improved Pipeline Pilot and KNIME components to extend deployment
options and enterprise support for ADMET Predictor - Updates to output displays in MedChem Designer™
- And more…
Dr.
David Miller, director of ADMET cheminformatics, said: “Our team of
talented scientists and software engineers introduced a significant
amount of innovative functionality, not available in other software, in
this release of ADMET Predictor. In particular, the ability of chemists
to now ‘see’ how a molecule could be optimized for important ADMET
properties tells a story that can be easily communicated across
departments as research programs progress. This further establishes our
machine learning platform as an industry leader and will be welcomed by
clients.”
Lancaster division president, John
DiBella, added: “We continue to realize solid growth in the number
of companies, from small to large, and regulatory agencies that license
ADMET Predictor. Our best-in-class machine learning methods are now
being applied to more enzyme and transporter isoforms, which, when
paired with our physiologically-based pharmacokinetic models in
GastroPlus®, provide holistic insights to support discovery
research efforts. We are excited to demonstrate these new features in
version 9.5 and, coupled with recent investments in marketing and sales,
expect to see accelerated expansion of the client base.”
About Simulations Plus, Inc.
Simulations Plus, Inc., is a premier developer of drug discovery and
development software as well as a leading provider of both preclinical
and clinical pharmacometric consulting
services for regulatory submissions and quantitative
systems pharmacology models for drug-induced
liver injury, drug-induced
kidney injury, and nonalcoholic
fatty liver disease. The company is a global leader focused on
improving the ways scientists use knowledge and data to predict the
properties and outcomes of pharmaceutical, biotechnology, and chemical
agents. Our software is licensed to and used in the conduct of drug
research by major pharmaceutical, biotechnology, chemical, and consumer
goods companies and regulatory agencies worldwide. Our innovations in
integrating new and existing science in medicinal chemistry,
computational chemistry, pharmaceutical science, biology, and physiology
into our software have made us the leading software provider for physiologically
based pharmacokinetic modeling and simulation. For more information,
visit our website at www.simulations-plus.com.
Safe Harbor Statement Under the Private Securities Litigation Reform
Act of 1995 – With the exception of historical information, the
matters discussed in this press release are forward-looking statements
that involve a number of risks and uncertainties. Words like “believe,”
“expect” and “anticipate” mean that these are our best estimates as of
this writing, but that there can be no assurances that expected or
anticipated results or events will actually take place, so our actual
future results could differ significantly from those statements. Factors
that could cause or contribute to such differences include, but are not
limited to: our ability to maintain our competitive advantages,
acceptance of new software and improved versions of our existing
software by our customers, the general economics of the pharmaceutical
industry, our ability to finance growth, our ability to continue to
attract and retain highly qualified technical staff, our ability to
identify and close acquisitions on terms favorable to the Company, and a
sustainable market. Further information on our risk factors is contained
in our quarterly and annual reports and filed with the U.S. Securities
and Exchange Commission.
Follow us on Twitter
| LinkedIn
Contacts
Simulations Plus Investor Relations
Ms.
Renee Bouche
661-723-7723
renee@simulations-plus.com
Hayden IR
Mr. Cameron Donahue
651-653-1854
cameron@haydenir.com